The financial terms of the agreement were not disclosed.

CytoSorb is used to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS).

SIRS is caused by a wide range of life-threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.

Biocon will now have the exclusive, region-wide rights to distribute CytoSorb for all critical care applications in the intensive care unit (ICU) as well as cardiac surgery applications for India and select emerging countries.

Dr Abhijit Barve, president, R&D, Biocon, said: "While our initial focus has been on sepsis, physicians are increasingly identifying conditions where very high levels of cytokines are known to cause multiple organ failure. We also believe there is a significant unmet medical need to manage high risk patients undergoing cardiac surgery by using CytoSorb to control inflammation. We are excited about working together with CytoSorbents and look forward to playing an important role in advancing the clinical development of this product."

As part of the expanded agreement, Biocon will also play a prominent leadership role in the generation of new clinical evidence to support the adoption and usage of CytoSorb.

This includes commitments to conduct and publish results from multiple Investigator Initiated Trials (IITs) and patient case studies.

Dr Phillip Chan, CEO and president, CytoSorbents, stated: "We are very pleased to expand our relationship with Biocon, which has been an exceptional partner in launching CytoSorb in India. We take deep pride in the opportunity to potentially help more people in this part of the world by addressing a broader array of conditions...."